A Phase 2 interventional study of CD07805/47 Gel and Vehicle Gel in Rosacea, sponsored by Galderma R&D. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.
Among the 11 studies testing brimonidine in Rosacea, this one is the 4th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 3rd registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2010.
This study's enrollment of 269 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 205 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 9th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 2, and was the 9th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing brimonidine in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema associated with rosacea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: CD07805/47 Gel
Drug: CD07805/47 Gel
Drug: CD07805/47 Gel
Drug: Vehicle Gel
Drug: Vehicle Gel
Drug page: Brimonidine
CD07805/47 Gel 0.5% QD
Vehicle Gel QD
Drug page: Brimonidine
CD07805/47 Gel 0.18% QD
Drug page: Brimonidine
CD07805/47 Gel 0.18% BID
Vehicle Gel BID
Composite Success
Composite success defined as 2-grade improvement on Clinician Erythema Assessment (CEA)and Patient Self Assessment-5 (PSA-5). Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
Time frame: Day 29
CEA Success
CEA success defined as 2-grade improvement on CEA. Each concentration/regimen was compared to its respective placebo control as part of the primary analysis. Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Amost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness
Time frame: Day 29
PSA-5 Success
Each concentration/regimen was compared to its respective placebo control as part of the primary analysis. PSA-5 success defined as 2-grade improvement on PSA-5. Patient Self Assessment - 5 (PSA-5) - Grade/description 0 / No redness 1. / Very mild redness 2. / Mild redness 3. / Moderate redness 4. / Severe redness
Time frame: day 29
| Milestone | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID |
|---|---|---|---|---|---|
| Started | 53 | 54 | 54 | 55 | 53 |
| Completed | 51 | 52 | 52 | 53 | 52 |
| Not completed | 2 | 2 | 2 | 2 | 1 |
Composite success defined as 2-grade improvement on Clinician Erythema Assessment (CEA)and Patient Self Assessment-5 (PSA-5). Each concentration/regimen was compared to its respective placebo control as part of the primary analysis.
| participants | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID |
|---|---|---|---|---|---|
| Day 29/Hour 3 | 16 | 10 | 10 | 2 | 4 |
| Day 29/Hour 6 | 15 | 10 | 9 | 4 | 7 |
| Day 29/Hour 9 | 17 | 7 | 11 | 2 | 10 |
| Day 29/Hour 12 | 10 | 5 | 8 | 2 | 9 |
CEA success defined as 2-grade improvement on CEA. Each concentration/regimen was compared to its respective placebo control as part of the primary analysis. Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Amost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness
| participants | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID |
|---|---|---|---|---|---|
| Day 29/Hour 3 | 27 | 21 | 22 | 12 | 9 |
| Day 29/Hour 6 | 23 | 21 | 18 | 12 | 12 |
| Day 29/Hour 9 | 26 | 20 | 23 | 12 | 15 |
| Day 29/Hour 12 | 20 | 17 | 18 | 12 | 16 |
Each concentration/regimen was compared to its respective placebo control as part of the primary analysis. PSA-5 success defined as 2-grade improvement on PSA-5. Patient Self Assessment - 5 (PSA-5) - Grade/description 0 / No redness 1. / Very mild redness 2. / Mild redness 3. / Moderate redness 4. / Severe redness
| participants | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID |
|---|---|---|---|---|---|
| Day 29/Hour 3 | 25 | 17 | 20 | 7 | 11 |
| Day 29/Hour 6 | 26 | 13 | 15 | 8 | 11 |
| Day 29/Hour 9 | 22 | 9 | 19 | 5 | 13 |
| Day 29/Hour 12 | 20 | 9 | 16 | 5 | 10 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD07805/47 Gel 0.5% QD | — | 0/53 (0%) | 18/53 (34%) |
| CD07805/47 Gel 0.18% QD | — | 1/54 (1.9%) | 13/54 (24.1%) |
| CD07805/47 Gel 0.18% BID | — | 0/54 (0%) | 14/54 (25.9%) |
| Vehicle Gel QD | — | 1/55 (1.8%) | 16/55 (29.1%) |
| Vehicle Gel BID | — | 0/53 (0%) | 8/53 (15.1%) |
| Event | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID |
|---|---|---|---|---|---|
| Gastric RefluxGastrointestinal disorders | 0/53 | 1/54 | 0/54 | 0/55 | 0/53 |
| Deep Vein ThrombosisVascular disorders | 0/53 | 0/54 | 0/54 | 1/55 | 0/53 |
| Event | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID |
|---|---|---|---|---|---|
| Intraocular pressure increasedEye disorders | 7/53 | 6/54 | 8/54 | 9/55 | 4/53 |
| FlushingVascular disorders | 4/53 | 1/54 | 0/54 | 0/55 | 0/53 |
| HeadacheNervous system disorders | 4/53 | 3/54 | 3/54 | 1/55 | 0/53 |
| PruritusSkin and subcutaneous tissue disorders | 3/53 | 3/54 | 1/54 | 4/55 | 0/53 |
| Skin Burning SensationSkin and subcutaneous tissue disorders | 3/53 | 1/54 | 2/54 | 1/55 | 0/53 |
| Skin WarmSkin and subcutaneous tissue disorders | 3/53 | 0/54 | 1/54 | 0/55 | 0/53 |
| SinusitisInfections and infestations | 0/53 | 1/54 | 0/54 | 2/55 | 3/53 |
| NasopharyngitisInfections and infestations | 2/53 | 0/54 | 1/54 | 3/55 | 1/53 |
| Age, Categorical(Participants) | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 52 | 50 | 50 | 54 | 51 | 257 |
| >=65 years | 1 | 4 | 4 | 1 | 2 | 12 |
| Age, Continuous(years) | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID | Total |
|---|---|---|---|---|---|---|
| Mean | 44.9 ± 11.50 | 46.9 ± 12.72 | 43.2 ± 12.28 | 43.4 ± 12.73 | 43.0 ± 12.33 | 44.3 ± 12.32 |
| Sex: Female, Male(Participants) | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID | Total |
|---|---|---|---|---|---|---|
| Female | 42 | 44 | 42 | 45 | 44 | 217 |
| Male | 11 | 10 | 12 | 10 | 9 | 52 |
| Region of Enrollment(participants) | CD07805/47 Gel 0.5% QD | CD07805/47 Gel 0.18% QD | CD07805/47 Gel 0.18% BID | Vehicle Gel QD | Vehicle Gel BID | Total |
|---|---|---|---|---|---|---|
| United States | 53 | 54 | 54 | 55 | 53 | 269 |
The record gives a start of Aug 2010, a primary completion of Dec 2010 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 3 years 3 months after primary completion. A results delay was requested in Jun 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine